Sodium glucose cotransporter SGLT1
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
... in glucose reabsorption The kidneys have a major role in glucose regulation in humans; under normal circumstances, over 99 % of the glu- cose filtered by the glomeruli is reabsorbed in the proximal tubules ...
13
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
... of sodium-glucose cotransporter-2 (SGLT2) ...blood glucose levels, but it is important to understand when to properly utilize ...Dual SGLT1/SGLT2 inhibitors are cur- rently being ...
12
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
... This led to extensive studies, which eventually led to the development of longer acting and more selective SGLT2 inhibitors, which were found to be effective antidiabetic agents and suitable for once-daily dosing without ...
7
DAPAGLIFLOZIN: NEWER MOLECULE FOR TREATMENT OF TYPE 2 DIABETES MELLITUS
... blood glucose levels in the ...of glucose and actively reabsorb virtually all of ...of glucose is filtered and reabsorbed by the kidneys despite the fact that this perpetuates the ...occurs, ...
9
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
... Method and results: ADDENDA‑BHS2 is a prospective, single‑center, active ‐ controlled, open, randomized trial. Ninety‑eight participants (40–70 years old) with HbA1c 7–9% were randomized (1:1, stratified by gender, BMI ...
12
Stem cells as a potential therapy for diabetes mellitus: a call-to-action in Latin America
... The pancreas is the major organ that systematically regulates glucose homeostasis. Pancreatic development involves the specific interplay of factors that, among other mechanisms, influence stem cell ...
13
SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
... lose glucose through the kidneys to different extents from early in life throughout the life span without experiencing any relevant morbidity or mortality related to this ...
12
SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2), A NEW APPROACH IN TYPE 2 DIABETES MELLITUS TREATMENT
... glucose reabsorption in the kidneys and some neurotransmitter dysfunction, are also involved in the pathophysiology of T2DM. [1] The currently available antidiabetic agents have been developed to target one or ...
11
Protein kinase C–mediated sodium glucose transporter 1 activation in precondition-induced cardioprotection
... and SGLT1, molecular modeling studies were conducted to elucidate the interaction of PKC–SGLT1 ...and SGLT1, and the PKC phosphorylation site in SGLT1 indicated that PKC acti- vates ...
10
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
... Differences also exist within drug classes. Exenatide and liraglutide have slightly better weight and efficacy out- comes compared to other GLP-1RA. Once-daily or weekly formulations may be preferred by patients and ...
11
Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
... by gavage twice a day. Because several of the measure- ments performed required rat sacrifice or the use of both kidneys, each of the above-mentioned experimental groups was subdivided to evaluate 1) blood pressure, 2) ...
9
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
... with sodium-glucose cotrans- porter 2 (SGLT2) inhibitor (empagliflozin) [1], two CV outcomes trials with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have also demonstrated superior ...
6
Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls
... of sodium and water that ultimately leads to an impaired ability to concentrate urine ...various sodium transporters are differentially expressed in rats with chronic renal failure (CRF) ...in sodium ...
15
The molecular basis of enhanced glucose transporter, SGLT1, expression in the diabetic intestine
... Diabetes(mellitus(is(effectively(managed(by(multimodal(intensive(therapies( to(maintain(glucose(homeostasis(and(to(minimize(the(risk(of(complications.(In(type( ...
227
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
... Several limitations to the current study should be noted. First, although the db/db model used in the current study is the most widely used mouse model of T2D, and db/db mice do display gut dysbiosis [56], the ...
14
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
... significant reduction in HbA 1c at 12 weeks compared with baseline of 0.79%, 0.76%, 0.70%, 0.92%, and 0.95% for canagliflozin 50, 100, 200, and 300 mg once daily and 300 mg twice daily, respectively, versus 0.22% for ...
15
Mechanism Underlying Increase of the Serum Magnesium Concentration Observed Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors
... oral glucose tolerance test (OGTT); or (iii) casual plasma glucose level of ≥200 mg/dL ...plasma glucose values (any of criteria) and the HbA1c ≥ ...
8
Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
... DAPA-HF, a large randomized clinical trial, investi- gated whether dapagliflozin improves long-term cardio- vascular outcomes among patients with heart failure with reduced ejection fraction regardless of diabetic sta- ...
6
Effects of galacto-oligosaccharides on growth and gut function of newborn suckling piglets
... In recent years, probiotics and prebiotics have gained considerable attention as growth promoters. Galacto-oli- gosaccharides (GOS), a type of prebiotics, contain 2-8 saccharide units, where one of these units is ...
11
The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management
... in glucose homeo- stasis, the kidney has become a target of drug therapy for the treatment of type 2 ...of glucose by inhibition of SGLT2, the transporter responsible for the majority of glucose ...
5